Neuland Laboratories Limited

BSE:524558 Stock Report

Market Cap: ₹138.7b

Neuland Laboratories Past Earnings Performance

Past criteria checks 2/6

Neuland Laboratories has been growing earnings at an average annual rate of 47.5%, while the Pharmaceuticals industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 16.6% per year. Neuland Laboratories's return on equity is 21.5%, and it has net margins of 19.6%.

Key information

47.5%

Earnings growth rate

47.5%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate16.6%
Return on equity21.5%
Net Margin19.6%
Last Earnings Update31 Dec 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Neuland Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:524558 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2415,3352,9992,6900
30 Sep 2415,2832,7972,6530
30 Jun 2416,3523,3612,7120
31 Mar 2415,5863,0012,5800
31 Dec 2315,8093,1712,4490
30 Sep 2314,5742,6622,3080
30 Jun 2313,3332,1542,1420
31 Mar 2311,9151,6352,0260
31 Dec 2210,4061,0081,9690
30 Sep 2210,0788311,9340
30 Jun 229,7206511,8840
31 Mar 229,5176381,8320
31 Dec 219,4005931,8260
30 Sep 219,4897311,7250
30 Jun 219,3247421,5890
31 Mar 219,3708061,5050
31 Dec 208,8525401,4000
30 Sep 208,4363841,3310
30 Jun 207,8842571,2920
31 Mar 207,6401621,2420
31 Dec 197,4433211,2160
30 Sep 197,1202571,1920
30 Jun 196,9452161,1550
31 Mar 196,6751641,1300
31 Mar 185,2841211,0550
31 Mar 175,7894691,0100
31 Mar 165,1002738470
31 Mar 154,6921596450
31 Mar 144,657268815108

Quality Earnings: 524558 has a large one-off gain of ₹803.2M impacting its last 12 months of financial results to 31st December, 2024.

Growing Profit Margin: 524558's current net profit margins (19.6%) are lower than last year (20.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 524558's earnings have grown significantly by 47.5% per year over the past 5 years.

Accelerating Growth: 524558's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 524558 had negative earnings growth (-5.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20.7%).

Return on Equity

High ROE: 524558's Return on Equity (21.5%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/17 22:29
End of Day Share Price 2025/03/17 00:00
Earnings2024/12/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Neuland Laboratories Limited is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Srivathsan RamachandranAvendus Spark
Rohit BhatBatlivala & Karani Securities India Pvt. Ltd.
Kameswari V. S. ChavaliFirstCall Research